A Study of IBI363 in Subjects With Advanced Melanoma

Recruiting now · Phase 2

Conditions studied: Melanoma

In brief

This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients

Key facts

Study ID

NCT06081920

Run by

Innovent Biologics (Suzhou) Co. Ltd.

People needed

180

Starts

2023-10-19

Expected to finish

2028-10-19

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically and/or cytologically confirmed, unresectable, locally advanced or metastatic melanoma (according to the American Joint Committee on Cancer (AJCC) 8th edition staging III-IV). Progression or recurrence after at least first-line systemic standard treatment.
• At least one measurable lesion (target lesion) per RECIST v1.1.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
• Life expectancy of 3 months or more.
• Female subjects of childbearing age or male subjects whose partners are female subjects of childbearing age agree to strictly adopt effective contraceptive measures throughout the entire treatment period and 6 months after the treatment period.

You may not qualify if…

• Pregnant or lactating subjects, or subjects who plan to conceive before, during, or within 6 months after the last dose of the study drug.
• Active or symptomatic central nervous system metastasis.
• At baseline (within 7 days before the first administration of the study drug), there were any hematological abnormalities as follows: hemoglobin<90 g/L; Absolute neutrophil count (ANC)<1.5 × 109/L; Platelet count<100 × 109/L.
• At baseline (within 7 days prior to first administration), there were any serum biochemical abnormalities as follows: Total bilirubin>1.5 × ULN; AST or ALT>3 × ULN; If it is tumor liver metastasis, AST or ALT>5.0 × ULN; Serum creatinine>1.5 × ULN or CCr<45 mL/min, using the Cockcroft Fault formula to calculate CCr (using actual body weight); Albumin<30 g/L.
• At baseline (within 7 days before first administration), there were any coagulation parameter abnormalities as follows: INR>1.5 × ULN (>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN); PTT (or activated partial thromboplastin time (aPTT))>1.5 × ULN (>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN).
• History of active thrombosis, deep vein thrombosis, or pulmonary embolism within 4 weeks prior to the first administration of the investigational drug, unless sufficient treatment has been given and the investigator believes that the condition is stable.
• Uncontrolled bleeding or known tendency to bleed.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Peking University Cancer Hospital & Institute, Beijing, China, — Beijing, Beijing Municipality, China (enrolling)
• Fujian Cancer Hospital — Fuzhou, Fujian, China (enrolling)
• The Third people's hospital of Zhengzhou — Zhengzhou, Henan, China (enrolling)
• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)
• Nanjing Drum Tower Hospital — Nanjing, Jiangsu, China (enrolling)
• The first affiliated hospital of Nanchang university — Nanchang, Jiangxi, China (enrolling)
• Jilin Cancer Hospital — Changchun, Jilin, China (enrolling)
• The first hospital of Jilin University — Changchun, Jilin, China (enrolling)
• Qilu Hospital of Shandong university — Jinan, Shandong, China (enrolling)
• Shanxi Bethune Hospital — Taiyuan, Shanxi, China (enrolling)
• Yunan Cancer Hospital — Kunming, Yunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.